Evidence map›Paper›PMID 27682233›Full record

ReviewMicroorganisms2014

The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12(®).

Mikkel Jungersen, Anette Wind, Eric Johansen, Jeffrey E Christensen, Birgitte Stuer-Lauridsen, Dorte Eskesen

Open access · goldAbstract readReview
In one paragraph

Review in Microorganisms, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 260 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Nutrients · 2021
    Trial
  9. Trial
  10. Trial
  11. Effect of theNutrients · 2020
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Article
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mikkel JungersenScientific Affairs, Chr Hansen A/S, Hørsholm DK-2970, Denmark. dkmkj@chr-hansen.com.
Anette WindCultures and Enzymes Division-Innovation, Chr Hansen A/S, Hørsholm DK-2970, Denmark. dkawi@chr-hansen.com.
Eric JohansenCultures and Enzymes Division-Innovation, Chr Hansen A/S, Hørsholm DK-2970, Denmark. dkejo@chr-hansen.com.
Jeffrey E ChristensenHealth and Nutrition Division-Innovation, Chr Hansen A/S, Hørsholm DK-2970, Denmark. dkjyc@chr-hansen.com.
Birgitte Stuer-LauridsenCultures and Enzymes Division-Innovation, Chr Hansen A/S, Hørsholm DK-2970, Denmark. dkbsl@chr-hansen.com.
Dorte EskesenScientific Affairs, Chr Hansen A/S, Hørsholm DK-2970, Denmark. dkdoe@chr-hansen.com.
Chr. Hansen (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review presents selected data on the probiotic strain Bifidobacterium animalis subsp. lactis BB-12(®) (BB-12(®)), which is the world's most documented probiotic Bifidobacterium. It is described in more than 300 scientific publications out of which more than 130 are publications of human clinical studies. The complete genome sequence of BB-12(®) has been determined and published. BB-12(®) originates from Chr. Hansen's collection of dairy cultures and has high stability in foods and as freeze dried powders. Strain characteristics and mechanisms of BB-12(®) have been established through extensive in vitro testing. BB-12(®) exhibits excellent gastric acid and bile tolerance; it contains bile salt hydrolase, and has strong mucus adherence properties, all valuable probiotic characteristics. Pathogen inhibition, barrier function enhancement, and immune interactions are mechanisms that all have been demonstrated for BB-12(®). BB-12(®) has proven its beneficial health effect in numerous clinical studies within gastrointestinal health and immune function. Clinical studies have demonstrated survival of BB-12(®) through the gastrointestinal tract and BB-12(®) has been shown to support a healthy gastrointestinal microbiota. Furthermore, BB-12(®) has been shown to improve bowel function, to have a protective effect against diarrhea, and to reduce side effects of antibiotic treatment, such as antibiotic-associated diarrhea. In terms of immune function, clinical studies have shown that BB-12(®) increases the body's resistance to common respiratory infections as well as reduces the incidence of acute respiratory tract infections.

Indexed as

BB-12®Bifidobacteriumprobiotic

Identifiers

PMID27682233
PMCPMC5029483
OpenAlexW2093843655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.